Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
11 déc. 2024 07h05 HE
|
Celcuity Inc.
Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with a...
Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update
14 nov. 2024 16h01 HE
|
Celcuity Inc.
The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash...
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences
12 nov. 2024 07h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
07 nov. 2024 07h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update
14 août 2024 16h01 HE
|
Celcuity Inc.
Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast...
Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call
07 août 2024 07h05 HE
|
Celcuity Inc.
MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
Celcuity To Participate in Jefferies Global Healthcare Conference
03 juin 2024 16h01 HE
|
Celcuity Inc.
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Celcuity Announces Pricing of Underwritten Common Stock Offering
30 mai 2024 07h36 HE
|
Celcuity Inc.
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the...
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
30 mai 2024 07h00 HE
|
Celcuity Inc.
The Phase 3 clinical trial will evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy...
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
15 mai 2024 16h01 HE
|
Celcuity Inc.
The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024First patient dosed in a Phase 1b/2 clinical trial evaluating...